AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

Investing.com - JPMorgan has reiterated its Overweight rating and $200.00 price target on AbbVie (NYSE: ABBV), currently valued at $337 billion, ahead of the company’s second-quarter earnings ...

In other recent news, AbbVie has announced an exclusive licensing agreement with IGI Therapeutics for ISB 2001, a trispecific antibody targeting multiple myeloma.

In 2024, macroeconomic uncertainty, election year volatility, and weakened consumer confidence led many corporations to adopt a more cautious approach, resulting in subdued dividend growth. - All ...

President Trump is amping up trade threats, again unveiling a new batch of letters to country leaders outlining tariffs on ...

President Trump is pushing through with his tariff agenda, unveiling a new batch of letters to country leaders outlining ...

President Trump is again amping up his trade threats, unveiling a new batch of letters to country leaders outlining tariffs ...

Get the latest The Hershey Company (HSY) stock news and headlines to help you in your trading and investing decisions.

US Stock Market Today saw the Dow rise while the Nasdaq dipped as investors balanced Nvidias $4 trillion milestone with new Trump tariff threats. Nvidia (NVDA) led recent tech gains, but President ...